Health
FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger – Business Wire
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. Breakthrough Designation entitles the platform to an expedited regulatory process.
…
-
Business23 hours agoWhy Amotiv, Breville, Life360, and Woodside shares are tumbling today
-
Noosa News24 hours agoBrisbane at centre of Queensland’s illegal cigarette boom
-
Noosa News22 hours agoDingoes bite 3 women on K’gari
-
Noosa News14 hours agoBrisbane doctor jailed for trafficking ‘breathtaking amount’ of drugs